MARKET

DRRX

DRRX

DURECT
NASDAQ

Real-time Quotes | Nasdaq Last Sale

1.690
-0.070
-3.98%
After Hours: 1.690 0 0.00% 16:00 09/23 EDT
OPEN
1.740
PREV CLOSE
1.760
HIGH
1.800
LOW
1.690
VOLUME
1.06M
TURNOVER
--
52 WEEK HIGH
3.949
52 WEEK LOW
0.9502
MARKET CAP
338.97M
P/E (TTM)
-120.7143
1D
5D
1M
3M
1Y
5Y
News
Financial
Releases
Corp Actions
Analysis
Profile
Dosing underway for Durect' DUR-928 in mid-stage COVID-19 study
Durect ([[DRRX]] -3.1%) has dosed the first patient in its Phase 2 study, evaluating DUR-928 in hospitalized COVID-19 patients with acute liver or kidney injury.The 80-subject trial is designed to
Seekingalpha · 12h ago
DURECT Corporation Announces First Patient Dosed in Phase 2 Safety and Efficacy Study of DUR-928 in COVID-19 Patients with Acute Liver or Kidney Injury
DURECT Corporation (Nasdaq: DRRX) today announced it has dosed the first patient in its randomized, double-blind, placebo-controlled, multi-center Phase 2 study to evaluate the safety and efficacy of DUR-928 in hospitalized COVID-19 patients with acute liver or kidney injury. The primary efficacy endpoint
PR Newswire · 12h ago
DURECT Corporation Announces First Patient Dosed In Phase 2 Safety And Efficacy Study Of DUR-928 In COVID-19 Patients With Acute Liver Or Kidney Injury
CUPERTINO, Calif., Sept. 23, 2020 /PRNewswire/ -- DURECT Corporation (NASDAQ:DRRX) today announced it has dosed the first patient in its randomized, double-blind, placebo-controlled, multi-center
Benzinga · 13h ago
DURECT Corporation Announces Design Of Phase 2b AHFIRM AH Study
CUPERTINO, Calif., Sept. 22, 2020 /PRNewswire/ --DURECT Corporation (NASDAQ:DRRX) today announced the study design for the Phase 2b AHFIRM clinical trial of DUR-928 in severe alcoholic hepatitis
Benzinga · 1d ago
DURECT Corporation to Participate in September Virtual Investor Conferences
DURECT Corporation (Nasdaq: DRRX) today announced that it will participate in the HC Wainwright 22nd Annual Global Investment Conference, Cantor Fitzgerald Virtual Global Healthcare Conference and Oppenheimer Fall Healthcare Life Sciences & MedTech Summit.
PR Newswire · 09/10 13:30
Durect (DRRX) Investor Presentation - Slideshow
The following slide deck was published by DURECT Corporation in conjunction with this event.
Seekingalpha · 08/28 21:02
DURECT Corporation Announces Presentation of Phase 2a Pharmacokinetic Data of DUR-928 in Alcoholic Hepatitis at Digital International Liver Congress (EASL)
DURECT Corporation (Nasdaq: DRRX) today announced the presentation of pharmacokinetic (PK) data from a Phase 2a study of DUR-928 in alcoholic hepatitis (AH) at the Digital International Liver Congress™ 2020 (EASL), taking place on August 27-29. DUR-928 was well tolerated at all doses tested in 19 AH
PR Newswire · 08/27 13:30
DURECT Corporation Fireside Chat hosted by Ellie Merle of Cantor Fitzgerald
DURECT Corporation (Nasdaq: DRRX) announced today that James E. Brown, President, CEO, Michael H. Arenberg, Chief Financial Officer and Dr. WeiQi Lin, Executive Vice President of R&D; will be participating in a fireside chat hosted by Ellie Merle of Cantor Fitzgerald, tomorrow, Thursday, August 27, 2020
PR Newswire · 08/26 21:30
More
Forecast
EPSBVPSCFPS
Actual (USD)
Estimate (USD)
Income StatementMore
Net IncomeTotal RevenueOperating Income
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
OperatingInvestingFinancing
Operating (USD)
YoY (%)
Learn about the latest financial forecast of DRRX. Analyze the recent business situations of DURECT through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 4 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average DRRX stock price target is 5.75 with a high estimate of 7.00 and a low estimate of 5.00.
EPS
Institutional Holdings
Institutions: 143
Institutional Holdings: 142.93M
% Owned: 71.26%
Shares Outstanding: 200.58M
TypeInstitutionsShares
Increased
27
20.81M
New
50
-857.40K
Decreased
22
3.79M
Sold Out
0
0
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
-2.78%
Pharmaceuticals & Medical Research
-1.14%
Key Executives
Chairman/Independent Director
David Hoffmann
President/Chief Executive Officer/Director
James Brown
Chief Financial Officer
Michael Arenberg
Senior Vice President
Judy Joice
Independent Director
Simon Benito
Independent Director
Terrence Blaschke
Independent Director
Gail Farfel
Independent Director
Armand Neukermans
Independent Director
Judith Robertson
Independent Director
Jon Saxe
  • Dividends
  • Splits
  • Insider Activity
No Data
Access Level 2 Advance
Nasdaq TotalView
for Free
Get Now
About DRRX
Durect Corporation is a biopharmaceutical company with research and development programs. The Company's products candidates include DUR-928, oral for metabolic/lipid disorders, and DUR-928, injectable for acute organ injuries. Its other product candidates include POSIMIR (controlled release injection of bupivacaine), REMOXY (oral controlled release oxycodone), ORADUR-ADHD, ELADUR (controlled release injection of bupivicane), Relday (risperidone), ORADUR-based opioid (hydromorphone) and SABER-based ophthalmic. The Company's ALZET product line consists of miniature, implantable osmotic pumps and accessories used for experimental research in mice, rats and other laboratory animals. The Company also manufactures and sells osmotic pumps used in laboratory research and design; and develops and manufactures a range of standard and custom biodegradable polymers and excipients for pharmaceutical and medical device clients for use as raw materials in their products.
More
Hot Stocks
Symbol
Price
%Change

Webull offers kinds of DURECT Corporation stock information, including NASDAQ:DRRX real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, DRRX stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading DRRX stock methods without spending real money on the virtual paper trading platform.